VICL Vical Incorporated

0.85
0  0%
Previous Close 0.85
Open 0.87
Price To Book 0.44
Market Cap 19,399,309
Shares 22,822,716
Volume 129,800
Short Ratio
Av. Daily Volume 237,745

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released September 19, 2016 did not meet primary endpoint.
ASP0113 Vaccine
Kidney transplant recipients
Phase 2 trial did not meet primary endpoint - June 11, 2018.
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Data did not meet primary endpoint
Vaxfectin-formulated therapeutic vaccine
Herpes
Phase 3 data released January 22, 2018 - endpoints not met.
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3 trial to be initiated 4Q 2019 with data due 4Q 2020.
Sofpironium Bromide
Axillary hyperhidrosis